A red-light-activated sulfonamide porphycene for highly efficient photodynamic therapy against hypoxic tumor

  • Yuzhi Wang
  • , Zhaohai Pan
  • , Xiao Lan Cheng
  • , Kai Zhang
  • , Xin Zhang
  • , Yao Qin
  • , Jiaojiao Fan
  • , Ting Yan
  • , Tao Han
  • , Kwok Keung Shiu
  • , Sam Chun-Kit Hau
  • , Nai Ki Mak
  • , Daniel W J Kwong
  • , Xiaona Liu
  • , Minjing Li
  • , Guowei Deng
  • , Qiusheng Zheng
  • , Jun Lu*
  • , Defang Li*
  • *Corresponding author for this work

Research output: Contribution to journalJournal articlepeer-review

13 Citations (Scopus)

Abstract

Photodynamic therapy (PDT) is an emerging alternative cancer treatment modality that utilizes photo-sensitivity to cause cell death upon photo-irradiation. However, PDT efficiency has been hampered by tumor hypoxia, blue-shifted excitation wavelengths, and the high dark toxicity of photo-sensitizers. We designed and synthesized two novel porphycene-based photosensitizers (TBPoS-OH and TBPoS-2OH) with potent photo-cytotoxicity and a LD50 in the nM range under both normoxic and hypoxic conditions in a variety of cell types after photo-irradiation (λ = 640 ± 15 nm). Further studies showed fast-cellular uptake for TBPoS-OH that localized lysosomes and subsequently induced cell apoptosis via the lysosomal-mitochondrial pathway. Moreover, TBPoS-OH significantly reduced tumor growth in two xenografted mouse models bearing melanoma A375 and B16 cells. Finally, TBPoS-OH exhibited no obvious immunogenicity and toxicity to blood cells and major organs in mice. These data demonstrated that these two porphycene-based photosensitizers, especially TBPoS-OH, could be developed as a potential PDT modality.

Original languageEnglish
Article number112867
JournalEuropean Journal of Medicinal Chemistry
Volume209
Early online date24 Sept 2020
DOIs
Publication statusPublished - 1 Jan 2021

User-Defined Keywords

  • Hypoxic
  • Melanoma
  • Photodynamic therapy
  • Porphycene
  • Tumor

Fingerprint

Dive into the research topics of 'A red-light-activated sulfonamide porphycene for highly efficient photodynamic therapy against hypoxic tumor'. Together they form a unique fingerprint.

Cite this